AR081015A1 - Formulaciones de galactomananos oftalmicas estabilizadas. metodo. - Google Patents

Formulaciones de galactomananos oftalmicas estabilizadas. metodo.

Info

Publication number
AR081015A1
AR081015A1 ARP110101556A ARP110101556A AR081015A1 AR 081015 A1 AR081015 A1 AR 081015A1 AR P110101556 A ARP110101556 A AR P110101556A AR P110101556 A ARP110101556 A AR P110101556A AR 081015 A1 AR081015 A1 AR 081015A1
Authority
AR
Argentina
Prior art keywords
formulations
galactomans
ophthalmic
stabilized ophthalmic
guar
Prior art date
Application number
ARP110101556A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of AR081015A1 publication Critical patent/AR081015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones oftálmicas de viscosidad estabilizada y formulaciones oftálmicas adecuadas para suministrar fármacos. Las formulaciones comprenden galactomananos tales como guar o guar de hidroxipropilo y una fuente de borato tal como ácido borico. Las formulaciones comprenden además un alcohol diol tal como sorbitol y, opcionalmente, una sal de cation divalente farmacéuticamente aceptable tal como cloruro de magnesio.
ARP110101556A 2010-05-05 2011-05-05 Formulaciones de galactomananos oftalmicas estabilizadas. metodo. AR081015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33151110P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
AR081015A1 true AR081015A1 (es) 2012-05-30

Family

ID=44626461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101556A AR081015A1 (es) 2010-05-05 2011-05-05 Formulaciones de galactomananos oftalmicas estabilizadas. metodo.

Country Status (16)

Country Link
US (2) US20110275593A1 (es)
EP (1) EP2566447B1 (es)
JP (1) JP5794744B2 (es)
KR (2) KR20180001587A (es)
CN (2) CN102939074A (es)
AR (1) AR081015A1 (es)
AU (1) AU2011248129B2 (es)
BR (1) BR112012028308B1 (es)
CA (1) CA2798069C (es)
ES (1) ES2809304T3 (es)
MX (1) MX2012012826A (es)
NZ (1) NZ603345A (es)
SG (2) SG10201804305SA (es)
TW (1) TWI606841B (es)
WO (1) WO2011140203A2 (es)
ZA (1) ZA201208199B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132294A1 (en) * 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
UA113434C2 (uk) * 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
CN109414441A (zh) 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
US11583496B2 (en) 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
CN115089547A (zh) * 2016-10-12 2022-09-23 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
TWI757773B (zh) * 2019-06-28 2022-03-11 瑞士商愛爾康公司 眼用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8028A (en) * 1851-04-08 Hokse-poweb
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
DE3827561C1 (es) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
EP1348427B1 (en) * 1997-07-29 2008-04-09 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
GB9808461D0 (en) * 1998-04-22 1998-06-17 Innovative Tech Ltd Solid borate-diol interaction products
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20100021561A1 (en) * 2006-09-21 2010-01-28 Chowhan Masood A Self-preserved aqueous pharmaceutical compositions
TWI434926B (zh) 2006-12-11 2014-04-21 Alcon Res Ltd 眼用組成物中聚氧化乙烯-聚氧化丁烯（ｐｅｏ-ｐｂｏ）嵌段共聚物之使用
AR066901A1 (es) * 2007-05-18 2009-09-23 Alcon Mfg Ltd Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas
WO2009132294A1 (en) * 2008-04-26 2009-10-29 Alcon Research, Ltd. Polymeric artificial tear system
BRPI1008654A2 (pt) 2009-02-05 2016-03-08 Alcon Res Ltd processo para purificação de guar

Also Published As

Publication number Publication date
TWI606841B (zh) 2017-12-01
ZA201208199B (en) 2014-01-29
US20130244971A1 (en) 2013-09-19
CN106389325A (zh) 2017-02-15
AU2011248129A1 (en) 2012-11-29
KR20180001587A (ko) 2018-01-04
SG10201804305SA (en) 2018-06-28
ES2809304T3 (es) 2021-03-03
CN102939074A (zh) 2013-02-20
US8846641B2 (en) 2014-09-30
EP2566447B1 (en) 2020-07-15
BR112012028308B1 (pt) 2021-09-28
BR112012028308A2 (pt) 2016-11-01
CA2798069C (en) 2016-07-05
TW201141524A (en) 2011-12-01
WO2011140203A2 (en) 2011-11-10
CA2798069A1 (en) 2011-11-10
NZ603345A (en) 2014-12-24
SG185422A1 (en) 2012-12-28
US20110275593A1 (en) 2011-11-10
KR20130060228A (ko) 2013-06-07
AU2011248129B2 (en) 2014-10-09
WO2011140203A3 (en) 2012-04-19
MX2012012826A (es) 2013-01-28
JP2013525493A (ja) 2013-06-20
JP5794744B2 (ja) 2015-10-14
EP2566447A2 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
AR081015A1 (es) Formulaciones de galactomananos oftalmicas estabilizadas. metodo.
IN2014DN03233A (es)
HK1201473A1 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
HK1202418A1 (en) Drug delivery system for sustained delivery of bioactive agents
BR112014032990A2 (pt) seringa
NZ702663A (en) Nuclear transport modulators and uses thereof
EP3064222A4 (en) Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
PE20140255A1 (es) Tableta dispersable en forma oral
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
AR090930A1 (es) Composiciones oftalmicas con proteccion mejorada contra la desecacion y retencion
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
IL227651A (en) Topical pharmacological formulations containing 220b
EA201391743A1 (ru) Фармацевтическая композиция, содержащая дротаверин
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
PE20142328A1 (es) Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliosido n-glicolil gm3 (neugcgm3)
MX2011005899A (es) Composicion farmacéutica con antihistamínico no sedante y combinaciones.
CO7141425A2 (es) Composiciones oftálmicas con retención y protección de desecación mejoradas
UA78605U (en) Pharmaceutical composition
UA85352U (ru) Фармацевтический продукт, содержащий налбуфин
TN2013000470A1 (en) Pharmaceutical composition comprising fexofenadine

Legal Events

Date Code Title Description
FB Suspension of granting procedure